- Home
- CUBI vs SUPN Comparison
CUBI vs SUPN Comparison
Compare CUBI & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBI
- SUPN
- Stock Information
- Founded
- CUBI 1994
- SUPN 2005
- Country
- CUBI United States
- SUPN United States
- Employees
- CUBI N/A
- SUPN N/A
- Industry
- CUBI Major Banks
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- CUBI Finance
- SUPN Health Care
- Exchange
- CUBI Nasdaq
- SUPN Nasdaq
- Market Cap
- CUBI 1.7B
- SUPN 1.8B
- IPO Year
- CUBI 2012
- SUPN 2012
- Fundamental
- Price
- CUBI $63.29
- SUPN $32.66
- Analyst Decision
- CUBI Buy
- SUPN Hold
- Analyst Count
- CUBI 9
- SUPN 2
- Target Price
- CUBI $67.38
- SUPN $36.00
- AVG Volume (30 Days)
- CUBI 374.6K
- SUPN 744.1K
- Earning Date
- CUBI 07-24-2025
- SUPN 08-05-2025
- Dividend Yield
- CUBI N/A
- SUPN N/A
- EPS Growth
- CUBI N/A
- SUPN N/A
- EPS
- CUBI 3.98
- SUPN 1.11
- Revenue
- CUBI $591,500,000.00
- SUPN $667,997,000.00
- Revenue This Year
- CUBI $12.60
- SUPN N/A
- Revenue Next Year
- CUBI $10.57
- SUPN $12.02
- P/E Ratio
- CUBI $16.05
- SUPN $29.53
- Revenue Growth
- CUBI N/A
- SUPN 11.82
- 52 Week Low
- CUBI $40.75
- SUPN $27.05
- 52 Week High
- CUBI $68.49
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- CUBI 63.33
- SUPN 56.20
- Support Level
- CUBI $61.49
- SUPN $32.20
- Resistance Level
- CUBI $65.46
- SUPN $34.40
- Average True Range (ATR)
- CUBI 1.93
- SUPN 0.99
- MACD
- CUBI -0.30
- SUPN 0.08
- Stochastic Oscillator
- CUBI 33.22
- SUPN 65.08
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.